Adaptive pathways promise a "triple win”.
They enable early access for patients to the most promising innovative therapies, address concerns over affordability, cost-effectiveness and outcome uncertainty for payers, whilst meeting companies’ need to make R&D sustainable.
As such they are a critical tool in the market access toolbox, but their opportunities and challenges are not well understood.
Uncertainty remains on how to realise all the potential benefits, when adaptive pathways are superior to traditional market entry routes, and how to overcome real-world evidence generation challenges.
This Masterclass addresses these strategic issues, illuminating when adaptive pathways are optimal for innovative therapies, as well as bringing together multiple perspectives on these iterative pathways.
Participants will benefit from engaging with OHE’s global thought leaders, and from industry insights on successful examples of adaptive pathways applications, which have aligned regulatory and reimbursement evidentiary requirements to enable timely access to breakthrough therapies.
The Masterclass speakers will also reflect on the practical opportunities and potential barriers to the acceptability of real-world evidence, and will present optimal evidence generation plans for different treatment types.
Full details and booking available here.
With its devastating and far-reaching consequences, the pandemic has made clear that health and wealth are inextricably interlinked. The rapid development and introduction of new interventions to fight COVID-19 has also demonstrated that the value of healthcare interventions go far beyond narrowly defined patient benefits.
What is the real value of a highly effective vaccine for COVID-19? What wouldn’t a society pay to rid itself of the virus?
Whilst the broader value of treatments and vaccines are acknowledged at the height of the pandemic, it is critical that in the post-pandemic recovery period, that health systems invest in interventions that create the greatest value.
The 2021 Masterclass Series will take attendees through the journey of exploring value from multiple perspectives, providing tools to identify consolidated and novel sources of value, and generate compelling evidence to demonstrate them.
Whilst value assessments are necessary to ensure that healthcare expenditure is optimal, there is also a need for a common understanding of what constitutes value, capturing what matters most to patients, society, and payers.
“Demonstrating Value: evolving with innovation” will explore this lively technical and policy debate, where the evolving and sometimes challenging nature of innovative interventions is not always matched by the value assessment paradigms applied by country decision-makers.
OHE’s 2021 Masterclass may be virtual but its excellence will be real. Join OHE experts and a faculty of international thought-leaders in this stimulating and insightful series on Demonstrating Value.
- To gain a deep-dive on theory and real-world evidence on the current debate on the value of innovative interventions to patients, healthcare systems and society, and anticipate future developments
- To discuss and understand opportunities and barriers for the incorporation of broader sources of value which matter the most to patients and society, in terms of payers and decision-makers acceptability and evidence requirements
- To understand the optimal approaches and solutions to improve patients, health systems and industry outcomes in areas of high unmet need such as rare diseases